Matching articles for "vonoprazan"
Issue 1713 · October 14, 2024 Free
Vonoprazan (Voquezna) for Nonerosive GERD

The potassium-competitive acid blocker vonoprazan ( Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):164-6 doi:10.58347/tml.2024.1713c
The potassium-competitive acid blocker vonoprazan ( Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) in adults. Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection.
Issue 1692 · December 25, 2023
Vonoprazan (Voquezna) for Erosive Esophagitis

The FDA has approved vonoprazan ( Voquezna – Phathom), a potassium-competitive acid blocker, for healing and maintenance of healing of all grades of erosive esophagitis and relief of associated heartburn in…

Med Lett Drugs Ther. 2023 Dec 25; 65(1692):203-5 doi:10.58347/tml.2023.1692b
The FDA has approved vonoprazan ( Voquezna – Phathom), a potassium-competitive acid blocker, for healing and maintenance of healing of all grades of erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults.
Issue 1662 · October 31, 2022
Two Vonoprazan Combinations (Voquezna) for H. pylori

The FDA has approved vonoprazan, a potassium-competitive acid blocker, copackaged with amoxicillin ( Voquezna Dual Pak – Phathom) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment…

Med Lett Drugs Ther. 2022 Oct 31; 64(1662):169-72
The FDA has approved vonoprazan, a potassium-competitive acid blocker, copackaged with amoxicillin ( Voquezna Dual Pak – Phathom) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults. Vonoprazan is the first potassium-competitive acid blocker to be approved in the US. It has been available in Japan for treatment of various acid-related disorders since 2014. Vonoprazan is not available alone in the US.
Issue 1647 · April 4, 2022
Drugs for GERD and Peptic Ulcer Disease

Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.

Med Lett Drugs Ther. 2022 Apr 4; 64(1647):49-56
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.